Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock
Abstract Purpose To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock. Summary The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, sho...
Gespeichert in:
Veröffentlicht in: | American journal of health-system pharmacy 2022-09, Vol.79 (19), p.1626-1633 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1633 |
---|---|
container_issue | 19 |
container_start_page | 1626 |
container_title | American journal of health-system pharmacy |
container_volume | 79 |
creator | Ragoonanan, David Tran, Nicolas Modi, Veeshal Morgan Nickelsen, Paige |
description | Abstract
Purpose
To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock.
Summary
The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, shock, and critical care. Articles relevant to HAT therapy in patients with septic shock were selected. Retrospective cohorts and randomized controlled trials were included in this review; case reports/series were excluded. Data from included studies illustrating the use of HAT therapy for the management of sepsis and septic shock, including data on time to HAT therapy initiation, severity of illness at baseline, duration of vasopressor therapy, progression of organ failure, and mortality, were evaluated.
Conclusion
The utilization of HAT therapy for the management of sepsis and septic shock remains controversial. Hemodynamic benefits have been shown to be most pronounced when HAT therapy is initiated earlier. Future studies directed at earlier initiation may be necessary to confirm this theory. |
doi_str_mv | 10.1093/ajhp/zxac169 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2676926311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ajhp/zxac169</oup_id><sourcerecordid>2676926311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-d0defdb77620bf7c8acd8351dc74812b0ba037ba9ad15897b40cf811624ec1073</originalsourceid><addsrcrecordid>eNp9kL1PwzAQxS0EonxtzMgbDA2c7SZORlTxJVVigTlybEd1ae3gSwTlr8elhZHp3ul-96T3CDlncM2gEjdqMe9uvj6VZkW1R45YLvKMVwD7SYOsMg4lH5FjxAUA4yUUh2QkcgkMyvyIvL965fHDRmvo-2Cxd8EjDZ72c0sHtDS0dL42MegQe4fB2zFVmJbGaaq0M2n1JtFOrZy3m7eoujV1nqLt0OHPOck-8TgP-u2UHLRqifZsN0_I6_3dy_Qxmz0_PE1vZ5kWXPSZAWNb00hZcGhaqUulTSlyZrSclIw30CgQslGVMiwvK9lMQLclYwWfWJ2CixNytfXtYvhJVq8cartcKm_DgDUvZFHxQjCW0PEW1TEgRtvWXXQrFdc1g3pTcr0pud6VnPCLnfPQrKz5g39bTcDlFghD97_VNypEiNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2676926311</pqid></control><display><type>article</type><title>Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock</title><source>Oxford Journals</source><creator>Ragoonanan, David ; Tran, Nicolas ; Modi, Veeshal ; Morgan Nickelsen, Paige</creator><creatorcontrib>Ragoonanan, David ; Tran, Nicolas ; Modi, Veeshal ; Morgan Nickelsen, Paige</creatorcontrib><description>Abstract
Purpose
To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock.
Summary
The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, shock, and critical care. Articles relevant to HAT therapy in patients with septic shock were selected. Retrospective cohorts and randomized controlled trials were included in this review; case reports/series were excluded. Data from included studies illustrating the use of HAT therapy for the management of sepsis and septic shock, including data on time to HAT therapy initiation, severity of illness at baseline, duration of vasopressor therapy, progression of organ failure, and mortality, were evaluated.
Conclusion
The utilization of HAT therapy for the management of sepsis and septic shock remains controversial. Hemodynamic benefits have been shown to be most pronounced when HAT therapy is initiated earlier. Future studies directed at earlier initiation may be necessary to confirm this theory.</description><identifier>ISSN: 1079-2082</identifier><identifier>EISSN: 1535-2900</identifier><identifier>DOI: 10.1093/ajhp/zxac169</identifier><identifier>PMID: 35701085</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>American journal of health-system pharmacy, 2022-09, Vol.79 (19), p.1626-1633</ispartof><rights>American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2022</rights><rights>American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-d0defdb77620bf7c8acd8351dc74812b0ba037ba9ad15897b40cf811624ec1073</citedby><cites>FETCH-LOGICAL-c323t-d0defdb77620bf7c8acd8351dc74812b0ba037ba9ad15897b40cf811624ec1073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1583,27915,27916</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35701085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ragoonanan, David</creatorcontrib><creatorcontrib>Tran, Nicolas</creatorcontrib><creatorcontrib>Modi, Veeshal</creatorcontrib><creatorcontrib>Morgan Nickelsen, Paige</creatorcontrib><title>Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock</title><title>American journal of health-system pharmacy</title><addtitle>Am J Health Syst Pharm</addtitle><description>Abstract
Purpose
To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock.
Summary
The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, shock, and critical care. Articles relevant to HAT therapy in patients with septic shock were selected. Retrospective cohorts and randomized controlled trials were included in this review; case reports/series were excluded. Data from included studies illustrating the use of HAT therapy for the management of sepsis and septic shock, including data on time to HAT therapy initiation, severity of illness at baseline, duration of vasopressor therapy, progression of organ failure, and mortality, were evaluated.
Conclusion
The utilization of HAT therapy for the management of sepsis and septic shock remains controversial. Hemodynamic benefits have been shown to be most pronounced when HAT therapy is initiated earlier. Future studies directed at earlier initiation may be necessary to confirm this theory.</description><issn>1079-2082</issn><issn>1535-2900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kL1PwzAQxS0EonxtzMgbDA2c7SZORlTxJVVigTlybEd1ae3gSwTlr8elhZHp3ul-96T3CDlncM2gEjdqMe9uvj6VZkW1R45YLvKMVwD7SYOsMg4lH5FjxAUA4yUUh2QkcgkMyvyIvL965fHDRmvo-2Cxd8EjDZ72c0sHtDS0dL42MegQe4fB2zFVmJbGaaq0M2n1JtFOrZy3m7eoujV1nqLt0OHPOck-8TgP-u2UHLRqifZsN0_I6_3dy_Qxmz0_PE1vZ5kWXPSZAWNb00hZcGhaqUulTSlyZrSclIw30CgQslGVMiwvK9lMQLclYwWfWJ2CixNytfXtYvhJVq8cartcKm_DgDUvZFHxQjCW0PEW1TEgRtvWXXQrFdc1g3pTcr0pud6VnPCLnfPQrKz5g39bTcDlFghD97_VNypEiNQ</recordid><startdate>20220922</startdate><enddate>20220922</enddate><creator>Ragoonanan, David</creator><creator>Tran, Nicolas</creator><creator>Modi, Veeshal</creator><creator>Morgan Nickelsen, Paige</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220922</creationdate><title>Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock</title><author>Ragoonanan, David ; Tran, Nicolas ; Modi, Veeshal ; Morgan Nickelsen, Paige</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-d0defdb77620bf7c8acd8351dc74812b0ba037ba9ad15897b40cf811624ec1073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ragoonanan, David</creatorcontrib><creatorcontrib>Tran, Nicolas</creatorcontrib><creatorcontrib>Modi, Veeshal</creatorcontrib><creatorcontrib>Morgan Nickelsen, Paige</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of health-system pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ragoonanan, David</au><au>Tran, Nicolas</au><au>Modi, Veeshal</au><au>Morgan Nickelsen, Paige</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock</atitle><jtitle>American journal of health-system pharmacy</jtitle><addtitle>Am J Health Syst Pharm</addtitle><date>2022-09-22</date><risdate>2022</risdate><volume>79</volume><issue>19</issue><spage>1626</spage><epage>1633</epage><pages>1626-1633</pages><issn>1079-2082</issn><eissn>1535-2900</eissn><abstract>Abstract
Purpose
To evaluate current evidence on the utility of hydrocortisone, ascorbic acid, and thiamine (HAT) therapy for the management of septic shock.
Summary
The following keyword search terms were utilized in PubMed to identify relevant articles: ascorbic acid, thiamine, hydrocortisone, shock, and critical care. Articles relevant to HAT therapy in patients with septic shock were selected. Retrospective cohorts and randomized controlled trials were included in this review; case reports/series were excluded. Data from included studies illustrating the use of HAT therapy for the management of sepsis and septic shock, including data on time to HAT therapy initiation, severity of illness at baseline, duration of vasopressor therapy, progression of organ failure, and mortality, were evaluated.
Conclusion
The utilization of HAT therapy for the management of sepsis and septic shock remains controversial. Hemodynamic benefits have been shown to be most pronounced when HAT therapy is initiated earlier. Future studies directed at earlier initiation may be necessary to confirm this theory.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>35701085</pmid><doi>10.1093/ajhp/zxac169</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1079-2082 |
ispartof | American journal of health-system pharmacy, 2022-09, Vol.79 (19), p.1626-1633 |
issn | 1079-2082 1535-2900 |
language | eng |
recordid | cdi_proquest_miscellaneous_2676926311 |
source | Oxford Journals |
title | Unanswered questions on the use of hydrocortisone, ascorbic acid, and thiamine therapy in sepsis and septic shock |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T17%3A43%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unanswered%20questions%20on%20the%20use%20of%20hydrocortisone,%20ascorbic%20acid,%20and%20thiamine%20therapy%20in%20sepsis%20and%20septic%20shock&rft.jtitle=American%20journal%20of%20health-system%20pharmacy&rft.au=Ragoonanan,%20David&rft.date=2022-09-22&rft.volume=79&rft.issue=19&rft.spage=1626&rft.epage=1633&rft.pages=1626-1633&rft.issn=1079-2082&rft.eissn=1535-2900&rft_id=info:doi/10.1093/ajhp/zxac169&rft_dat=%3Cproquest_cross%3E2676926311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2676926311&rft_id=info:pmid/35701085&rft_oup_id=10.1093/ajhp/zxac169&rfr_iscdi=true |